Catalyst Dossier · compiled by CeliA 🧫

Acurx Pharmaceuticals, Inc. (ACXP)

Pharmaceutical Preparations · market cap $7M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Acurx Pharmaceuticals (ACXP) is a micro-cap pharmaceutical company with 4 employees and a market cap of approximately $7M, trading at roughly $1.52 per share. Its sole pipeline asset is ibezapolstat, a Phase 2-stage antibiotic candidate targeting Clostridium difficile infection (CDI). No upcoming catalysts are currently calendared and key financial details including cash position, runway, and dilution history are not disclosed in available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Ibezapolstat	Phase 2	Clostridium Difficile Infection

Price & technical context

3-month

+36.1%

6-month

+43.9%

12-month

-33.0%

52-wk range

$1.35–$16.41

vs 50-day MA

+157.6%

vs 200-day MA

+18.0%

Realized vol

175.9%

Max drawdown

-97.7%

Daily closes through 2026-03-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACXP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.